Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067735 | 0.89 | NPC1 (0.32) | — | |
| SCHEMBL900026 | 0.86 | — | — | |
| SCHEMBL1067923 | 0.85 | — | — | |
| SCHEMBL900707 | 0.84 | — | — | |
| SCHEMBL1064154 | 0.84 | — | — | |
| SCHEMBL1064625 | 0.84 | SCN8A (0.31) | — | |
| SCHEMBL456928 | 0.84 | ALDH1A1 (0.31) | — | |
| SCHEMBL28943837 | 0.84 | — | — | |
| SCHEMBL15353224 | 0.84 | L3MBTL1 (0.36) | — | |
| SCHEMBL1067659 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | claimed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | claimed |
| EP-1345942-B9 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-11-15 | — | — | EP | claimed |
| US-7081455-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-25 | — | — | US | claimed |
| US-7071186-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2006-07-04 | — | — | US | claimed |
| EP-1345942-B1 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-03-01 | — | — | EP | claimed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | claimed |
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-21 | — | — | US | claimed |
| EP-1189905-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1189904-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | claimed |
| US-6638934-B2 | 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-28 | — | — | US | claimed |
| EP-1345942-A2 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030153576-A1 | Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-08-14 | — | — | US | claimed |
| US-6552017-B1 | As serotonin agonists and antagonists and are useful in the control or prophylaxis of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | claimed |
| US-6548493-B1 | Serotonin receptor modulators (5-HT2C and 5-HT2A); treating obesity, anxiety, depression, psychological disorders, migraine, sexual disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | claimed |
| JP-2003502336-A | — | — | 2003-01-21 | — | — | JP | claimed |
| US-20020177596-A1 | Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-28 | — | — | US | claimed |
| WO-2002059127-A2 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153576-A1 | Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands | HTR1A, HTR5A, HTR3A | GPR3 22/4885 |
| US-20020177596-A1 | Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands | HTR1A, HTR5A, HTR1D | GPR3 46/4885 |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | GPR3 224/4885 |
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | GPR3 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.